Table 1.
Study population's general characteristics (n = 121).
| Variable | Total, n (%) |
|---|---|
| Age (years, mean, SD) | 61 (10) |
| Sex (Female) | 61 (50.4%) |
| ASA score III-IV, yes | 24 (19.8%) |
| CACI >4, yes | 71 (58.7%) |
| Diabetes mellitus, yes | 27 (22.3%) |
| NLR (median, IQR) | 2.1 (2) |
| PLR (median, IQR) | 140 (59.8) |
| LMR (median, IQR) | 2.6 (2) |
| PNI (median, IQR) | 41 (4.8) |
| Albumin (g/L, median, IQR) | 41 (5.2) |
| Stage at diagnosis | |
| Borderline resectable | 92 (76) |
| Locally advanced | 29 (24) |
| Tumor size (mm, mean, SD) | |
| Pre-neoadjuvant therapy | 30.6 (8.9) |
| Post-neoadjuvant therapy | 24.3 (9.6) |
| Neoadjuvant therapy scheme | |
| FOLFIRINOX | 55 (45.4) |
| Gemcitabine/Nab-Paclitaxel | 33 (27.3) |
| Other | 23 (27.3) |
| Chemotherapy duration (cycles, median, IQR) | 5 (5) |
| Time diagnosis to surgery (mo, median, IQR) | 6 (5) |
| Vascular resection, yes | 24 (19.8%) |
| T-status at pathology | |
| Tx | 15 (12.4) |
| T1 | 31 (25.6) |
| T2 | 58 (47.9) |
| T3 | 4 (3.3) |
| T4 | 13 (10.7) |
| N-status at pathology | |
| N0 | 47 (38.8) |
| N1 | 46 (38) |
| N2 | 28 (23.2) |
| R0 resection, yes | 68 (56.2) |
| Length of stay (days), median (IQR) | 11 (9) |
| Postoperative morbidity (overall), yes | 61 (50.4%) |
| Major complications (Clavien-Dindo ≥ 3), yes | 15 (12.4%) |
NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lympho-cyte ratio; LMR, lymphocyte-to-monocyte ratio; PNI, prognostic nutritional index.